Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Immunoglobulin Light-chain Amyloidosis 3Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neurofibrosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Leukemia, Plasma Cell 1Hematologic Neoplasms 1Breast Neoplasms 1Advanced Non-hematologic Malignancies 1Advanced Cancers 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × ixazomib × Clear all
NCT03422874 2018-02-06

Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

Dartmouth-Hitchcock Medical Center

Phase 1 Withdrawn
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡